Russia has received a new batch of Trikafta (Elexacaftor/tezacaftor/ivacaftor and ivacaftor), 376 packages of tablets in a dosage of 50 mg/25 mg/37.5 mg; 75 mg No. 84. This is reported on the official website of the Circle of Kindness foundation for the support of children with orphan diseases.
“According to Sanofi, most of the received batch has already been delivered to a number of regions of the Russian Federation. These are the Altai Territory, the Volgograd Region, the Voronezh Region, the Krasnodar Territory, the Lipetsk Region, the Moscow Region, the Republic of Bashkortostan, the Republic of Buryatia, the Ryazan Region, St. Petersburg, the Tyumen Region, the Ulyanovsk Region, and the Khanty-Mansi Autonomous Okrug (Yugra). The drug is expected to be delivered to Moscow, the Nizhny Novgorod Region and the Republic of Tatarstan by the end of June 2022,” the Foundation reported.
The drug was approved in the United States in 2019 for patients aged over 12 years. It is suitable for about 90% of children with cystic fibrosis. An annual course of treatment with Trikafta costs 23 million rubles.
Russian President Vladimir Putin instructed to simplify the procedure for the import of medicines and medical devices purchased by the Circle of Kindness Foundation.
